Since Nogo-A was proven to induce tau hyperphosphorylation and exacerbate AD-associated pathology and cognitive decline, downregulation of Nogo-A may reverse AD progression and be an effective strategy to treat AD. The gene discussed is MAPT; the disease is Alzheimer disease.